These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28639412)

  • 21. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity.
    Toubi E; Kessel A; Grushko G; Sabo E; Rozenbaum M; Rosner I
    Clin Exp Rheumatol; 2002; 20(2):221-4. PubMed ID: 12051403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxidative stress in the pathogenesis of systemic scleroderma: An overview.
    Vona R; Giovannetti A; Gambardella L; Malorni W; Pietraforte D; Straface E
    J Cell Mol Med; 2018 Jul; 22(7):3308-3314. PubMed ID: 29664231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TGF-β-mediated downregulation of microRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts.
    Honda N; Jinnin M; Kajihara I; Makino T; Makino K; Masuguchi S; Fukushima S; Okamoto Y; Hasegawa M; Fujimoto M; Ihn H
    J Immunol; 2012 Apr; 188(7):3323-31. PubMed ID: 22379029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis.
    Kikuchi K; Kubo M; Sato S; Fujimoto M; Tamaki K
    J Am Acad Dermatol; 1995 Dec; 33(6):973-8. PubMed ID: 7490368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis.
    Maurer B; Stanczyk J; Jüngel A; Akhmetshina A; Trenkmann M; Brock M; Kowal-Bielecka O; Gay RE; Michel BA; Distler JH; Gay S; Distler O
    Arthritis Rheum; 2010 Jun; 62(6):1733-43. PubMed ID: 20201077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A reactive oxygen species-mediated loop maintains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis.
    Spadoni T; Svegliati Baroni S; Amico D; Albani L; Moroncini G; Avvedimento EV; Gabrielli A
    Arthritis Rheumatol; 2015 Jun; 67(6):1611-22. PubMed ID: 25707572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Critical roles of microRNAs in the pathogenesis of systemic sclerosis: New advances, challenges and potential directions.
    Miao CG; Xiong YY; Yu H; Zhang XL; Qin MS; Song TW; Du CL
    Int Immunopharmacol; 2015 Sep; 28(1):626-33. PubMed ID: 26241784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiopoietin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients.
    Carvalheiro T; Lopes AP; van der Kroef M; Malvar-Fernandez B; Rafael-Vidal C; Hinrichs AC; Servaas NH; Bonte-Mineur F; Kok MR; Beretta L; Zimmermann M; Marut W; Pego-Reigosa JM; Radstake TRDJ; Garcia S
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating miRNA-19b as a biomarker of disease progression and treatment response to baricitinib in rheumatoid arthritis patients through miRNA profiling of monocytes.
    Ciechomska M; Roszkowski L; Burakowski T; Massalska M; Felis-Giemza A; Roura AJ
    Front Immunol; 2023; 14():980247. PubMed ID: 37056771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulated IRF8 in Monocytes and Macrophages of Patients with Systemic Sclerosis May Aggravate the Fibrotic Phenotype.
    Ototake Y; Yamaguchi Y; Asami M; Komitsu N; Akita A; Watanabe T; Kanaoka M; Kurotaki D; Tamura T; Aihara M
    J Invest Dermatol; 2021 Aug; 141(8):1954-1963. PubMed ID: 33705797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced interleukin-10 production by dendritic cells upon stimulation with Toll-like receptor 4 agonists in systemic sclerosis that is possibly implicated in CCL18 secretion.
    van Lieshout AW; Vonk MC; Bredie SJ; Joosten LB; Netea MG; van Riel PL; Lafyatis R; van den Hoogen FH; Radstake TR
    Scand J Rheumatol; 2009; 38(4):282-90. PubMed ID: 19255934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone modifications underlie monocyte dysregulation in patients with systemic sclerosis, underlining the treatment potential of epigenetic targeting.
    van der Kroef M; Castellucci M; Mokry M; Cossu M; Garonzi M; Bossini-Castillo LM; Chouri E; Wichers CGK; Beretta L; Trombetta E; Silva-Cardoso S; Vazirpanah N; Carvalheiro T; Angiolilli C; Bekker CPJ; Affandi AJ; Reedquist KA; Bonte-Mineur F; Zirkzee EJM; Bazzoni F; Radstake TRDJ; Rossato M
    Ann Rheum Dis; 2019 Apr; 78(4):529-538. PubMed ID: 30793699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis.
    Blaise S; Maas R; Trocme C; Kom GD; Roustit M; Carpentier PH; Cracowski JL
    J Rheumatol; 2009 May; 36(5):984-8. PubMed ID: 19332631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated levels of TL1A are associated with disease activity in patients with systemic sclerosis.
    Xu W; Su L; Qing P; Wang Y; Liang Y; Zhao Y; Zhou Q; Ma F; Liu Y
    Clin Rheumatol; 2017 Jun; 36(6):1317-1324. PubMed ID: 28397078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global miRNA and mRNA expression profiles identify miRNA-26a-2-3p-dependent repression of IFN signature in systemic sclerosis human monocytes.
    Ciechomska M; Wojtas B; Swacha M; Olesinska M; Benes V; Maslinski W
    Eur J Immunol; 2020 Jul; 50(7):1057-1066. PubMed ID: 32087087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages.
    Kräling BM; Maul GG; Jimenez SA
    Pathobiology; 1995; 63(1):48-56. PubMed ID: 7546275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advances in animal models of systemic sclerosis.
    Asano Y
    J Dermatol; 2016 Jan; 43(1):19-28. PubMed ID: 26782003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased frequencies of circulating CXCL10-, CXCL8- and CCL4-producing monocytes and Siglec-3-expressing myeloid dendritic cells in systemic sclerosis patients.
    Carvalheiro T; Horta S; van Roon JAG; Santiago M; Salvador MJ; Trindade H; Radstake TRDJ; da Silva JAP; Paiva A
    Inflamm Res; 2018 Feb; 67(2):169-177. PubMed ID: 29127442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased release of soluble CD163 by the peripheral blood mononuclear cells is associated with worse prognosis in patients with systemic sclerosis.
    Bielecki M; Kowal K; Lapinska A; Chyczewski L; Kowal-Bielecka O
    Adv Med Sci; 2013; 58(1):126-33. PubMed ID: 23640944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exercise in systemic sclerosis intensifies systemic inflammation and oxidative stress.
    Hargardóttir H; van Helvoort HA; Vonk MC; van den Hoogen FH; Dekhuijzen PN; Heijdra YF
    Scand J Rheumatol; 2010; 39(1):63-70. PubMed ID: 20132073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.